Imipramine

GPTKB entity

Statements (50)
Predicate Object
gptkbp:instanceOf gptkb:drug
antidepressant
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode N06AA02
gptkbp:brand gptkb:Imavate
gptkb:Tofranil
Janimine
gptkbp:CASNumber 50-49-7
gptkbp:category gptkb:dibenzazepine
amphetamine
antidepressant
tricyclic compound
gptkbp:chemicalFormula C19H24N2
gptkbp:contraindication recent myocardial infarction
concurrent MAOI use
gptkbp:discoveredBy gptkb:Geigy
gptkbp:eliminationHalfLife 11–25 hours
gptkbp:firstSynthesized 1948
gptkbp:has_metabolite gptkb:desipramine
https://www.w3.org/2000/01/rdf-schema#label Imipramine
gptkbp:introduced 1957
gptkbp:IUPACName 3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
gptkbp:KEGGID D00334
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction norepinephrine reuptake inhibitor
gptkbp:meltingPoint 167–168 °C
gptkbp:metabolism liver
gptkbp:molecularWeight 280.41 g/mol
gptkbp:patent 1951
gptkbp:pregnancyCategory C (US)
gptkbp:PubChem_CID 3568
3696
CHEMBL654
DB00458
gptkbp:routeOfAdministration oral
intramuscular
gptkbp:sideEffect gptkb:orthostatic_hypotension
constipation
weight gain
drowsiness
dry mouth
sexual dysfunction
gptkbp:solubility slightly soluble in water
gptkbp:UNII 7BB9YJ8U49
gptkbp:usedFor gptkb:panic_disorder
gptkb:major_depressive_disorder
chronic pain
enuresis
gptkbp:bfsParent gptkb:Antidepressants
gptkbp:bfsLayer 6